About Monte Rosa Therapeutics, Inc.
https://www.monterosatx.comMonte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers.
CEO
Markus Warmuth
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 98
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
NEA MANAGEMENT COMPANY, LLC
Shares:7.69M
Value:$185.08M
BVF INC/IL
Shares:5.66M
Value:$136.18M
VERSANT VENTURE MANAGEMENT, LLC
Shares:5.65M
Value:$136.01M
Summary
Showing Top 3 of 135
About Monte Rosa Therapeutics, Inc.
https://www.monterosatx.comMonte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $12.77M ▼ | $43.65M ▲ | $-27.08M ▼ | -212.1% ▼ | $-0.33 ▼ | $-28.16M ▼ |
| Q2-2025 | $23.19M ▼ | $38.75M ▼ | $-12.29M ▼ | -53.01% ▼ | $-0.15 ▼ | $-13.43M ▼ |
| Q1-2025 | $84.93M ▲ | $40.89M ▼ | $46.88M ▲ | 55.2% ▲ | $0.57 ▲ | $46.08M ▲ |
| Q4-2024 | $60.65M ▲ | $47.64M ▲ | $13.44M ▲ | 22.16% ▲ | $0.22 ▲ | $15.06M ▲ |
| Q3-2024 | $9.22M | $35.74M | $-23.86M | -258.89% | $-0.29 | $-24.42M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $391.26M ▲ | $459.84M ▲ | $214M ▲ | $245.84M ▼ |
| Q2-2025 | $290.59M ▼ | $359.59M ▼ | $91.51M ▼ | $268.08M ▼ |
| Q1-2025 | $326.07M ▼ | $393.2M ▼ | $118.04M ▼ | $275.16M ▲ |
| Q4-2024 | $372.15M ▲ | $438.73M ▲ | $215.8M ▲ | $222.94M ▲ |
| Q3-2024 | $242.19M | $315.08M | $109.62M | $205.46M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-27.08M ▼ | $100.43M ▲ | $38.14M ▲ | $348K ▼ | $138.91M ▲ | $99.78M ▲ |
| Q2-2025 | $-12.29M ▼ | $-34.72M ▲ | $25.32M ▲ | $365K ▲ | $-9.03M ▲ | $-36.41M ▲ |
| Q1-2025 | $46.88M ▲ | $-45.49M ▼ | $-100.23M ▼ | $14K ▼ | $-145.72M ▼ | $-47.08M ▼ |
| Q4-2024 | $13.44M ▲ | $128.92M ▲ | $-30.9M ▼ | $608K ▲ | $98.63M ▲ | $128.74M ▲ |
| Q3-2024 | $-23.86M | $-20.99M | $37.75M | $15K | $16.77M | $-21.39M |
CEO
Markus Warmuth
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 98
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
NEA MANAGEMENT COMPANY, LLC
Shares:7.69M
Value:$185.08M
BVF INC/IL
Shares:5.66M
Value:$136.18M
VERSANT VENTURE MANAGEMENT, LLC
Shares:5.65M
Value:$136.01M
Summary
Showing Top 3 of 135